These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 8439971)

  • 1. In vitro and in vivo targeting of gene expression to melanoma cells.
    Vile RG; Hart IR
    Cancer Res; 1993 Mar; 53(5):962-7. PubMed ID: 8439971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo -- use of the human tyrosinase promoter with human enhancers.
    Lillehammer T; Tveito S; Engesaeter BO; Fodstad O; Maelandsmo GM; Engebraaten O
    Cancer Gene Ther; 2005 Nov; 12(11):864-72. PubMed ID: 15891771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells.
    Siders WM; Halloran PJ; Fenton RG
    Cancer Res; 1996 Dec; 56(24):5638-46. PubMed ID: 8971169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanoma-specific cytotoxicity induced by a tyrosinase promoter-enhancer/herpes simplex virus thymidine kinase adenovirus.
    Siders WM; Halloran PJ; Fenton RG
    Cancer Gene Ther; 1998; 5(5):281-91. PubMed ID: 9824047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA.
    Vile RG; Hart IR
    Cancer Res; 1993 Sep; 53(17):3860-4. PubMed ID: 8395331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MIA (melanoma inhibitory activity) promoter mediated tissue-specific suicide gene therapy of malignant melanoma.
    Schoensiegel F; Paschen A; Sieger S; Eskerski H; Mier W; Rothfels H; Kleinschmidt J; Schadendorf D; Haberkorn U
    Cancer Gene Ther; 2004 Jun; 11(6):408-18. PubMed ID: 15118759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats.
    Ram Z; Culver KW; Walbridge S; Blaese RM; Oldfield EH
    Cancer Res; 1993 Jan; 53(1):83-8. PubMed ID: 8380127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel nonviral cytoplasmic gene expression system and its implications in cancer gene therapy.
    Chen X; Li Y; Xiong K; Xie Y; Aizicovici S; Snodgrass R; Wagner TE; Platika D
    Cancer Gene Ther; 1995 Dec; 2(4):281-9. PubMed ID: 8548582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cotransfection of genes encoding human tyrosinase and tyrosinase-related protein-1 prevents melanocyte death and enhances melanin pigmentation and gene expression of Lamp-1.
    Luo D; Chen H; Jimbow K
    Exp Cell Res; 1994 Jul; 213(1):231-41. PubMed ID: 8020595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-copy bicistronic retroviral vector platform for gene therapy and tissue engineering: application to melanoma vaccine development.
    Wiznerowicz M; Fong AZ; Mackiewicz A; Hawley RG
    Gene Ther; 1997 Oct; 4(10):1061-8. PubMed ID: 9415312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An oncolytic adenoviral vector carrying the tyrosinase promoter for glioma gene therapy.
    Ulasov IV; Rivera AA; Nettelbeck DM; Rivera LB; Mathis JM; Sonabend AM; Tyler M; Wang M; Douglas JT; Lesniak MS
    Int J Oncol; 2007 Nov; 31(5):1177-85. PubMed ID: 17912445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A safe, effective in vivo gene therapy for melanoma using tyrosinase promoter-driven cytosine deaminase gene.
    Cao G; Zhang X; He X; Chen Q; Qi Z
    In Vivo; 1999; 13(2):181-7. PubMed ID: 10363176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes.
    Vile R; Miller N; Chernajovsky Y; Hart I
    Gene Ther; 1994 Sep; 1(5):307-16. PubMed ID: 7584096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A transcriptional feedback loop for tissue-specific expression of highly cytotoxic genes which incorporates an immunostimulatory component.
    Emiliusen L; Gough M; Bateman A; Ahmed A; Voellmy R; Chester J; Diaz RM; Harrington K; Vile R
    Gene Ther; 2001 Jul; 8(13):987-98. PubMed ID: 11438833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasmid DNA gene therapy: studies with the human interleukin-2 gene in tumor cells in vitro and in the murine B16 melanoma model in vivo.
    Parker SE; Khatibi S; Margalith M; Anderson D; Yankauckas M; Gromkowski SH; Latimer T; Lew D; Marquet M; Manthorpe M; Hobart P; Hersh E; Stopeck AT; Norman J
    Cancer Gene Ther; 1996; 3(3):175-85. PubMed ID: 8725882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
    Douin-Echinard V; Bornes S; Rochaix P; Tilkin AF; Peron JM; Bonnet J; Favre G; Couderc B
    Cancer Gene Ther; 2000 Dec; 7(12):1543-56. PubMed ID: 11228533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue specific promoters in targeting systemically delivered gene therapy.
    Hart IR
    Semin Oncol; 1996 Feb; 23(1):154-8. PubMed ID: 8607025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.
    Okada T; Caplen NJ; Ramsey WJ; Onodera M; Shimazaki K; Nomoto T; Ajalli R; Wildner O; Morris J; Kume A; Hamada H; Blaese RM; Ozawa K
    J Gene Med; 2004 Mar; 6(3):288-99. PubMed ID: 15026990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component.
    Vile RG; Nelson JA; Castleden S; Chong H; Hart IR
    Cancer Res; 1994 Dec; 54(23):6228-34. PubMed ID: 7954471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo interferon regulatory factor 3 tumor suppressor activity in B16 melanoma tumors.
    Duguay D; Mercier F; Stagg J; Martineau D; Bramson J; Servant M; Lin R; Galipeau J; Hiscott J
    Cancer Res; 2002 Sep; 62(18):5148-52. PubMed ID: 12234977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.